Compare Cadila Healthcare with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs J.B.CHEMICALS - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE J.B.CHEMICALS CADILA HEALTHCARE/
J.B.CHEMICALS
 
P/E (TTM) x 27.9 21.7 128.6% View Chart
P/BV x 3.3 3.9 85.4% View Chart
Dividend Yield % 1.0 0.3 343.3%  

Financials

 CADILA HEALTHCARE   J.B.CHEMICALS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
J.B.CHEMICALS
Mar-18
CADILA HEALTHCARE/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs432363 119.1%   
Low Rs306255 120.2%   
Sales per share (Unadj.) Rs128.6169.1 76.0%  
Earnings per share (Unadj.) Rs18.516.6 111.7%  
Cash flow per share (Unadj.) Rs24.423.4 104.2%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.90.6 146.4%  
Book value per share (Unadj.) Rs101.5172.5 58.8%  
Shares outstanding (eoy) m1,023.7483.57 1,225.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.91.8 157.2%   
Avg P/E ratio x19.918.6 107.0%  
P/CF ratio (eoy) x15.113.2 114.7%  
Price / Book Value ratio x3.61.8 203.2%  
Dividend payout %18.912.0 156.6%   
Avg Mkt Cap Rs m378,17025,827 1,464.2%   
No. of employees `00012.43.8 329.7%   
Total wages/salary Rs m21,2412,511 845.9%   
Avg. sales/employee Rs Th10,585.03,747.4 282.5%   
Avg. wages/employee Rs Th1,707.8665.7 256.5%   
Avg. net profit/employee Rs Th1,526.5367.8 415.1%   
INCOME DATA
Net Sales Rs m131,65614,135 931.4%  
Other income Rs m2,011366 549.8%   
Total revenues Rs m133,66714,501 921.8%   
Gross profit Rs m29,7312,178 1,364.9%  
Depreciation Rs m5,986570 1,050.7%   
Interest Rs m1,93535 5,544.4%   
Profit before tax Rs m23,8211,940 1,228.2%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,303552 960.2%   
Profit after tax Rs m18,9871,387 1,368.7%  
Gross profit margin %22.615.4 146.5%  
Effective tax rate %22.328.5 78.2%   
Net profit margin %14.49.8 147.0%  
BALANCE SHEET DATA
Current assets Rs m84,98110,470 811.7%   
Current liabilities Rs m73,4252,749 2,671.0%   
Net working cap to sales %8.854.6 16.1%  
Current ratio x1.23.8 30.4%  
Inventory Days Days7555 135.0%  
Debtors Days Days11078 141.0%  
Net fixed assets Rs m133,4935,811 2,297.2%   
Share capital Rs m1,024167 612.8%   
"Free" reserves Rs m102,83914,248 721.8%   
Net worth Rs m103,86314,416 720.5%   
Long term debt Rs m39,4970-   
Total assets Rs m234,83117,649 1,330.6%  
Interest coverage x13.356.6 23.5%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.60.8 70.0%   
Return on assets %8.98.1 110.6%  
Return on equity %18.39.6 190.0%  
Return on capital %18.313.7 133.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,4046,164 785.3%   
Fx outflow Rs m11,5931,334 868.8%   
Net fx Rs m36,8114,829 762.2%   
CASH FLOW
From Operations Rs m28,8231,231 2,342.4%  
From Investments Rs m-57,387-208 27,576.6%  
From Financial Activity Rs m18,846-595 -3,166.3%  
Net Cashflow Rs m-7,105427 -1,663.5%  

Share Holding

Indian Promoters % 74.8 55.4 135.0%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 8.3 3.4 244.8%  
FIIs % 5.9 3.9 151.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 37.0 29.7%  
Shareholders   44,069 30,437 144.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades Positive, Crude Oil Sees Buying, FPI Equity Inflows Rise, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended marginally lower yesterday as benchmark indices gave up early gains and slipped into the red during the last hour of trading.

Related Views on News

J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 26, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS